Differences in outcome between percutaneous coronary intervention and coronary bypass grafting Joseph S. Alpert Editor’s Commentary Pages: 173 - 174
The risk of congestive heart failure: sobering lessons from the framingham heart study Donald M. Lloyd-Jones OriginalPaper Pages: 184 - 190
Heart failure in blacks: Etiologic and epidemiologic differences Clyde W. Yancy OriginalPaper Pages: 191 - 197
Genomics and the pathophysiology of heart failure Juey-Jen HwangVictor J. DzauChoong-Chin Liew OriginalPaper Pages: 198 - 207
Novel neurohumoral factors in congestive heart failure: Adrenomedullin John G. Lainchbury OriginalPaper Pages: 208 - 214
Therapeutic options in patients with reduced ejection fraction and nonsustained ventricular tachycardia Eugen C. Palma OriginalPaper Pages: 219 - 223
Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving β-blocking agents Simon F. ShakarMichael R. Bristow OriginalPaper Pages: 224 - 231
The role of endothelin receptor antagonists in the treatment of chronic heart failure Wolfgang KiowskiGabor Sütsch OriginalPaper Pages: 232 - 240
Mitral ring annuloplasty: An incomplete correction of functional mitral regurgitation associated with left ventricular remodeling Justine LachmannJamshid ShiraniThierry H. LeJemtel OriginalPaper Pages: 241 - 246
The angiotensin-converting enzyme inhibitor and aspirin interaction in congestive heart failure:Fear or reality? Robert Moskowitz OriginalPaper Pages: 247 - 253
